Ostrum Asset Management’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$991K Buy
22,696
+651
+3% +$30.1K 0.05% 229
2026
Q2
$941K Sell
22,045
-9
-0% -$489 0.05% 231
2026
Q1
$1.38M Sell
22,054
-973
-4% -$77.8K 0.08% 183
2025
Q4
$2.2M Sell
23,027
-818
-3% -$80.2K 0.11% 151
2025
Q3
$2.33M Buy
23,845
+1,663
+7% +$172K 0.1% 173
2025
Q2
$2.38M Sell
22,182
-4,742
-18% -$480K 0.11% 175
2025
Q1
$2.72M Sell
26,924
-2,924
-10% -$294K 0.14% 141
2024
Q4
$2.67M Sell
29,848
-10,161
-25% -$894K 0.23% 132
2024
Q3
$3.35M Sell
40,009
-1,024
-2% -$80.7K 0.28% 109
2024
Q2
$3.16M Sell
41,033
-246
-0.6% -$18K 0.28% 106
2024
Q1
$2.83M Buy
41,279
+1,706
+4% +$110K 0.22% 142
2023
Q4
$2.29M Buy
39,573
+8,402
+27% +$448K 0.2% 168
2023
Q3
$1.65M Buy
31,171
+12,895
+71% +$676K 0.15% 210
2023
Q2
$989K Buy
18,276
+16
+0.1% +$836 0.08% 320
2023
Q1
$914K Buy
+18,260
New +$861K 0.08% 328

Other funds holding BSX

Ostrum Asset Management's BSX Position: Q3 2026 in Review

Ostrum Asset Management increased its Boston Scientific (BSX) stake by 3% in Q3 2026, buying an estimated $30.1K and bringing the position to 22,696 shares worth $991K. The position accounts for 0.05% of the portfolio, ranked #229.

Ostrum Asset Management first reported a position in BSX in Q1 2023 and has held it in 15 quarters since. The position peaked at $3.35M in Q3 2024. 1,274 funds tracked by Wall St. Rank hold BSX as of Q3 2026.

  • Ostrum Asset Management held 22,696 shares of Boston Scientific worth $991K as of Q3 2026.
  • Ostrum Asset Management bought 651 Boston Scientific shares in Q3 2026, an estimated $30.1K.
  • Boston Scientific made up 0.05% of Ostrum Asset Management's portfolio in Q3 2026, its #229 holding.
  • Ostrum Asset Management first reported a position in Boston Scientific in Q1 2023 and has held it in 15 quarters since.
  • Ostrum Asset Management's Boston Scientific position peaked at $3.35M in Q3 2024.
  • 1,274 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2026.

Based on Ostrum Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.